Orion published Interim Report January-September 2022 on Thursday, 20 October 2022. The report, related presentation material and webcast recording are available here.
|11/4/2022||Orion Corporation completed share acquisitions|
|11/4/2022||Orion Corporation: Acquisition of Own Shares 04.11.2022|
|11/3/2022||Orion Corporation: Acquisition of Own Shares 03.11.2022|
|11/2/2022||Orion Corporation: Acquisition of Own Shares 02.11.2022|
Possible requests from the shareholders to have a matter dealt with by Orion Corporation’s Annual General Meeting 2023 must be submitted to the Board of Directors of Orion Corporation no later than Monday, 16 January 2023.
|10/27/2022||Orion Research Foundation is awarding EUR 1 million in grants and two EUR 100,000 special grants today|
|10/6/2022||Orion publishes Interim Report for January–September 2022 on Thursday 20 October 2022|
|9/5/2022||Orion recalls Devisol Salmiakki dietary supplement from consumers|
|8/8/2022||U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)|
The Annual General Meeting of Orion Corporation was held on Wednesday 23 March 2022. The decisions and related material are available here.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
Orion’s virtual Capital Markets Day 2021 was held on 26 May 2021. Presentations and webcast from the event are available here.
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.